DEPARTMENT OF OPHTHALMOLOGY
RESEARCH DIVISION
The Loma Linda University Healthcare, Department of Ophthalmology would like to introduce you to our Research Division. Loma Linda has been actively involved in many clinical trials involving diseases of the eye. The following is a brief list and description of the type of research projects that we are actively involved in. If you are interested in having your patients participate in these studies, please contact our Research Department at (909) 558-2170 or (909) 558-2169 for more information.
Diabetic Eyes Studies
Disease: Diabetic Retinopathy
DRCR I:
Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser Photocoagulation for Diabetic Macular Edema
Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD & Mukesh B. Suthar, MD
Study Objective: To evaluate safety and efficacy of the following in eyes with center-involved DME
Intravitreal Ranibizumab in combination with focal laser Intravitreal Ranibizumab alone Intravitreal Triamcinolone in combination with focal laser
Major Eligibility Criteria: Age >=18 years Type 1 or type 2 diabetes Center involved DME responsible for visual acuity of 20/32 or worse OCT central subfield thickness 250 microns Subjects may have one or two study eyes
DRCR J:
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD & Mukesh B. Suthar, MD
Study Objective:
To determine whether intravitreal injection of an anti-VEGF drug or an intravitreal injection of a corticosteroid can reduce the risk of visual acuity impairment that can occur following PRP and increase the chances of at least short-term visual acuity improvement in eyes with evidence of center-involved macular edema that are undergoing PRP for severe NPDR or PDR.
- Age >=18 years
- Type 1 or type 2 diabetes
- Study eye with severe nonproliferative or proliferative diabetic retinopathy for which the investigator intends to perform full scatter photocoagulation
- Diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns)
Sample size 381 eyes (one per subject)
Regeneron Study (VEGF Trap - Reg 0605)
Principal Investigator: Joseph T. Fan, MD
Sub-Investigators: Michael E. Rauser, MD & Mukesh B. Suthar, MD
Sub-Investigators: Michael E. Rauser, MD & Mukesh B. Suthar, MD
Age-Related Macular Degeneration (AMD) is a leading cause of adult blindness in the developed world. Severe visual loss from AMD is caused by a combination of retinal edema and neovascular proliferation. Vascular Endothelial Growth Factor (VEGF), a protein growth factor that both stimulates angiogenesis and increases vascular permeability, is a major pathogenic factor in AMD. Counteracting these effects of VEGF provide significant therapeutic benefit to subjects suffering from this disorder.
Department of Ophthalmology
Research Division
11370 Anderson Street, Suite 1800
Loma Linda, CA 92354
This study assesses the efficacy of intravitreal (ITV) administered VEGF Trap compared to ranibizumab in a non-inferiority paradigm in preventing moderate vision loss in subjects with all subtypes of neovascular AMD.
Major eligibility criteria:
- Age >=18 years.
- Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye.
- ETDRS best-corrected visual acuity of: 20/40 to 20/320 (letter score of 73 to 25) in the study eye.
Through participation patients can expect to receive:
- No cost study drug at one of two study drug doses
- No cost study related eye exam
For more information please contact:
Research Division Staff
- Cara Davidson -(909) 558-2168
- Kara Rollins - (909) 558-2170
- Gisela Santiago - (909) 558-2169
Department of Ophthalmology
Research Division
11370 Anderson Street, Suite 1800
Loma Linda, CA 92354
